More recently, a significant advance in harnessing costimulation as a cancer immunotherapy has been the development of nonsuperagonistic and tumor-targeted CD28 bispecific antibodies that require a separate tumor-associated Signal 1 for efficacy (6–9). Here, CD28 is linked to neoplasm.